Octreotide Acetate Injection
| General Information: Octreotide acetate injection is typically utilized to reduce blood levels of growth hormone and IGF-I in acromegaly patients, for the syptomatic treatment of patients with metastatic carcinoid tumors, and vasoactive intestinal peptide tumors as described in the package insert. For indications, dosing and other information, please refer to the manufacture package insert.
|
| |
| Manufacturer |
Products |
Size |
NDC |
PI |
MSDS |
| TEVA |
Octreotide
Acetate |
50 mcg/mL (25 pack) |
00703-3301-04 |
PI |
MSDS |
| |
Octreotide
Acetate |
100 mcg/mL (25 pack) |
00703-3311-04 |
PI |
MSDS |
| |
Octreotide
Acetate |
500 mcg/mL (25 pack) |
00703-3321-04 |
PI |
MSDS |
| |
Octreotide
Acetate |
1000mcg/5mL |
00703-3333-01 |
PI |
MSDS |
| |
Octreotide
Acetate |
5000 mcg/5mL |
00703-3343-01 |
PI |
MSDS |
| |
|
|
|
|
|
| Caraco |
Octreotide Acetate |
100mcg/mL (10 pack) |
62756-0349-44 |
PI |
MSDS |
| |
Octreotide Acetate |
200mcg/5mL |
62756-0350-40 |
PI |
MSDS |
| |
Octreotide Acetate |
1000mcg/5mL |
62756-0352-40 |
PI |
MSDS |
| |
Octreotide Acetate |
500mcg/mL |
62756-0351-44 |
PI |
MSDS |
| |
Octreotide Acetate |
50mcg.mL |
62756-0348-44 |
PI |
MSDS |
|
| |
| Clinical Data:
For any questions or for further
information related to Octreotide acetate injection,
clinical pharmacology, additional indications and
usages, contraindications,
warnings, precautions, adverse
reactions, dosage,
administration and/or storage
of this product, please
contact
BDI Pharma or
call
1-800-948-9834. |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|